Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 12/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521572 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL16690101 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2521573 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2549985 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL30208193 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL16081101 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510991 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL850195 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510990 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL19821287 | 0.95 | BTN3A1 (0.47) | BTN3A1CYP3A4CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016181313-A1 | A PROCESS FOR THE PREPARATION OF SOFOSBUVIR INTERMEDIATES & ITS POLYMORPH | LUPIN LIMITED (IN) | 2016-11-17 | — | — | WO | claimed |
| EP-2552930-A2 | NUCLEOSIDE PHOSPHORAMIDATES | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| EP-4705313-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | The Scripps Research Institute (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062437-A1 | ANTIVIRAL COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2025235664-A1 | PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250282803-A1 | DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250109163-A1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | Atea Pharmaceuticals, Inc. (US) | 2025-04-03 | — | — | US | disclosed |
| WO-2025049569-A2 | EXTENDED PURINE TRICYCLIC AND BICYCLIC NUCLEOSIDES AND NUCLEOTIDES FOR USE AS ANTIVIRAL THERAPEUTICS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4511381-A1 | DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Rome Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011123668-A2 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123672-A1 | PURINE NUCLEOSIDE PHOSPHORAMIDATE | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010135569-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | PHARMASSET, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062437-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IFNAR1, IRF3 | BTN3A1 3335/4885CYP3A4 2578/4885CYP2C9 3181/4885 |
| US-20250109163-A1 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | HAVCR2, HCCS, SLC10A1 | BTN3A1 3397/4885CYP3A4 1930/4885CYP2C9 2514/4885 |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885CYP3A4 3916/4885CYP2C9 4098/4885 |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3738/4885CYP3A4 3811/4885CYP2C9 3971/4885 |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | BTN3A1 3359/4885CYP3A4 1919/4885CYP2C9 1843/4885 |
| US-20250282803-A1 | DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | DTYMK, DCK, POLK | BTN3A1 3447/4885CYP3A4 596/4885CYP2C9 932/4885 |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | BTN3A1 3601/4885CYP3A4 3916/4885CYP2C9 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.